Takeda at PTH1R
As of the edition of 20 October 2026, Takeda is on route B at PTH1R (parathyroid hormone/parathyroid hormone-related peptide receptor), position 9 of 2,016 on that route, with a score of 0.786.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.786
Biology proven in humans0.93
How much the company cares0.77
Room, and a reason to act now0.67
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Trials at the target more often meet than miss their main endpoint+0.138
Few other companies active at the target+0.128
Active at the target or its disease area recently+0.050
The company’s own follow-on drug+0.044
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 27 December 2019.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 23 January 2015.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 23 January 2015.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Parathyroid hormone | Marketed | Phase 4 | 36 | Computed: 12 years from first US licence: 23 January 2027 |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT01455181 | Parathyroid hormone | Phase 3 | Completed | 2011 to 2012 | 24 | No results posted |
| NCT01297309 | Parathyroid hormone | Phase 3 | Completed | 2011 to 2018 | 51 | No results posted |
| NCT01268098 | Parathyroid hormone | Phase 3 | Completed | 2011 to 2011 | 42 | Main endpoint missed |
| NCT00732615 | Parathyroid hormone | Phase 3 | Completed | 2008 to 2011 | 124 | Main endpoint met |
| NCT00583518 | Parathyroid hormone | Phase 4 | Completed | 2007 to 2012 | 129 | No results posted |
| NCT00478569 | Parathyroid hormone | Completed | 2007 to 2013 | 1,179 | No results posted | |
| NCT00515593 | Parathyroid hormone | Completed | 2006 to 2008 | 110 | No results posted | |
| NCT00365456 | Parathyroid hormone | Phase 3 | Completed | 2006 to 2011 | 407 | Main endpoint met |
| NCT00172120 | Parathyroid hormone | Phase 3 | Completed | 2005 to 2006 | 91 | No results posted |
| NCT00172133 | Parathyroid hormone | Phase 3 | Completed | 2001 to 2005 | 1,683 | No results posted |
| NCT00172081 | Parathyroid hormone | Phase 3 | Completed | 2000 to 2003 | 2,532 | No results posted |
| NCT00172107 | Parathyroid hormone | Phase 2 | Completed | 1995 to 1997 | 217 | No results posted |